Jun 1, 2026 02:53AM
May 30, 2026 08:00AM
May 12, 2026 09:30AM
May 7, 2026 08:50AM
May 7, 2026 08:50AM
May 3, 2026 12:00PM
May 1, 2026 05:28PM FDA approves Incyte's once-daily Jakafi XR for blood disorders
May 1, 2026 05:28PM
Apr 29, 2026 10:15AM
Apr 28, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 23, 2026 05:48AM
Apr 23, 2026 03:00AM MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
Apr 21, 2026 10:00AM
Apr 21, 2026 10:00AM
Apr 7, 2026 12:26PM
Apr 7, 2026 07:30AM
Apr 2, 2026 07:01AM
Apr 2, 2026 07:01AM
Mar 30, 2026 10:19AM William Blair on Incyte (INCY): 'encouraged' by Ph3 data and deepened responses
Mar 30, 2026 04:21AM
Mar 28, 2026 03:00PM
Mar 25, 2026 09:13AM
Mar 24, 2026 04:02PM
Mar 20, 2026 10:00AM
Mar 17, 2026 07:30AM
Mar 17, 2026 07:30AM Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
Mar 9, 2026 08:00AM
Feb 27, 2026 08:13AM
Feb 27, 2026 08:11AM
Feb 19, 2026 05:31PM
Feb 17, 2026 10:48AM
Feb 16, 2026 05:31PM
Feb 10, 2026 07:00AM Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
Jan 30, 2026 09:29AM
Jan 30, 2026 09:29AM
Jan 5, 2026 01:33PM
Jan 5, 2026 07:30AM
Jan 5, 2026 07:30AM
Dec 22, 2025 05:40AM
Dec 22, 2025 02:44AM Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Dec 22, 2025 02:42AM
Dec 17, 2025 11:20AM
Dec 17, 2025 11:20AM
Dec 8, 2025 04:30PM
Dec 8, 2025 04:30PM
Dec 8, 2025 02:53AM
Dec 8, 2025 02:53AM Incyte reports phase 1 data for myelofibrosis drug INCA033989
Dec 7, 2025 09:30AM

322,084 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All